Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer

DISEASE CHARACTERISTICS: * Histologically confirmed prostate cancer * Stage D0 disease * Tumor originally diagnosed as being limited to the prostate and now having a rising prostate-specific antigen (PSA) after definitive local therapy * Must have undergone local treatment via prostatectomy or radiotherapy * PSA values must be ≥ 0.2 ng/mL as determined by 2 measurements, ≥ 1 month apart and ≥ 6 months after prostatectomy * PSA values must be ≥ 2.0 ng/mL as determined by 2 measurements, ≥ 1 month apart and ≥ 6 months after radiotherapy * The first two PSA values along with a third value must all be rising (i.e., there must be an overall rising trajectory, such that the third value cannot be lower than the first value) * No metastatic disease by baseline bone scan and CT scan of the abdomen and/or pelvis PATIENT CHARACTERISTICS: * Life expectancy ≥ 6 months * ECOG performance status 0-2 * WBC ≥ 3,500/µL * ANC ≥ 1,500/µL * Platelet count \> 100,000/µL * Hemoglobin \> 10 g/dL * Serum creatinine \< 1.5 mg/dL OR creatinine clearance \> 50 mL/min * Total bilirubin normal * SGOT and/or SGPT normal * No serious concomitant systemic disorder that, at the discretion of the investigator, would compromise the safety of the patient or compromise the patient's ability to complete the study * No second primary malignancy within the past 5 years except adequately treated in situ carcinoma (e.g., non-melanomatous carcinoma of the skin) or other malignancy with no evidence of recurrence * No active clinically significant infection requiring antibiotics * No history of coronary artery disease * No myocardial infarction within the past 6 months * No sulfa allergy * No history of gastrointestinal bleeding PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior hormone-ablative treatment * Prior neoadjuvant hormone-ablative therapy allowed provided it was completed ≥ 3 months ago * More than 4 weeks since prior herbal products with hormonal activity such as soy, saw palmetto, or PC-SPES * No prior or concurrent nonsteroidal anti-inflammatory drug (NSAIDS) for 7 consecutive days * No COX-2 inhibitor and/or statin within the past 6 months * No concurrent warfarin or any other anticoagulant, calcitriol, fibric acid derivatives, lipid-modifying doses of niacin, or strong cytochrome P450 3A4 inhibitors (e.g., cyclosporine, erythromycin, clarithromycin, and azole antifungals) or inducers (e.g., St John wort) * No other concurrent anticancer agents or therapies including chemotherapy, hormonal therapy, radiotherapy, or experimental therapy